All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center and Temple Health Welcome Dr Claire L. Streibert

March 30th 2023

Fox Chase Cancer Center and Temple Health are pleased to announce the hiring of Claire L. Streibert, MD, as site chief of breast imaging.

FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer

March 30th 2023

The FDA has granted a fast track designation to RRx-001 for the prevention and attenuation of severe oral mucositis associated with chemotherapy and radiation in patients with head and neck cancer.

A New Generation of Cytokine-Based Immunotherapy Takes Shape

March 30th 2023

Nearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.

Amivantamab Provides Long-term Clinical Benefit in Post-Platinum EGFR Exon 20 Insertion+ NSCLC

March 30th 2023

Amivantamab continued to be tolerable and efficacious in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.

FDA Grants Full Approval to Pembrolizumab for Select Patients With MSI-H or dMMR Solid Tumors

March 29th 2023

The FDA has granted full approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient solid tumors that have progressed following previous treatment and who have no satisfactory alternative options.

Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC

March 29th 2023

Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.

TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC

March 29th 2023

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.

Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-onset Colorectal Cancer

March 29th 2023

Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it.

European Commission Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLC

March 29th 2023

The European Commission has approved cemiplimab-rwlc plus platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without EGFR, ALK, or ROS1 alterations and who are not eligible for chemoradiation.

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors

March 29th 2023

Blueprint Medicines announced on March 28, 2023, that the FDA has removed a partial clinical hold on the phase 1/2 VELA trial trial of BLU-222.

Encouraging Data Pave the Way for New Standards in CRC

March 29th 2023

As the development of systemic treatments for metastatic colorectal cancer move toward precision therapy, guidelines have adjusted to integrate decisions based on molecular drivers.

Severity of Patient-Reported Symptom Burden Remains Low and Stable After Adjuvant Systemic Treatment in CRC

March 29th 2023

Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.

Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian Cancer

March 28th 2023

Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.

FDA Issues Guidelines to Support Applications for Accelerated Approvals

March 28th 2023

The FDA has issued draft guidance to improve applications for accelerated approvals, according to a recently issued news release.

Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer

March 28th 2023

Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.

Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial Cancer

March 28th 2023

Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.

A New Combination Therapy Regimen Shows Promising Results For Prostate Cancer

March 28th 2023

TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.

Fixed-Duration Ibrutinib Plus Venetoclax Earns Approval in Canada for Previously Untreated CLL

March 28th 2023

Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.

Precision Medicine Takes On an Increasingly Relevant but Misunderstood Role in Oncology

March 28th 2023

The evaluation of diagnostic quality in precision medicine should almost certainly be assessed by standards different from those used in drug development.

Obe-cel May Prove a Tolerable Treatment Alternative in Relapsed/Refractory B-ALL

March 28th 2023

Sameem Abedin, MD, discusses where CAR T-cell therapy falls in the treatment paradigm for B-cell acute lymphoblastic leukemia, the known safety profile of obe-cel as evidenced in early studies, and how findings from the FELIX trial could change the future management of this disease.